These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38534508)

  • 21. Thoracic aortic disease in tuberous sclerosis complex: molecular pathogenesis and potential therapies in Tsc2+/- mice.
    Cao J; Gong L; Guo DC; Mietzsch U; Kuang SQ; Kwartler CS; Safi H; Estrera A; Gambello MJ; Milewicz DM
    Hum Mol Genet; 2010 May; 19(10):1908-20. PubMed ID: 20159776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
    Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
    Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetics of tuberous sclerosis complex: implications for clinical practice.
    Caban C; Khan N; Hasbani DM; Crino PB
    Appl Clin Genet; 2017; 10():1-8. PubMed ID: 28053551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tuberous sclerosis complex: A review].
    Pfirmann P; Combe C; Rigothier C
    Rev Med Interne; 2021 Oct; 42(10):714-721. PubMed ID: 33836894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical, cellular, and molecular characterisation of cardiac rhabdomyoma in tuberous sclerosis.
    Al Kindi HN; Ibrahim AM; Roshdy M; Abdelghany BS; Yehia D; Masoud AN; Simry W; Aguib Y; Yacoub MH
    Cardiol Young; 2021 Aug; 31(8):1297-1305. PubMed ID: 33602381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.
    Zucco AJ; Pozzo VD; Afinogenova A; Hart RP; Devinsky O; D'Arcangelo G
    Mol Cell Neurosci; 2018 Oct; 92():149-163. PubMed ID: 30144504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex.
    Lu Y; Zhang EY; Liu J; Yu JJ
    Orphanet J Rare Dis; 2020 Aug; 15(1):209. PubMed ID: 32807195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Finding a cure for tuberous sclerosis complex: From genetics through to targeted drug therapies.
    McEneaney LJ; Tee AR
    Adv Genet; 2019; 103():91-118. PubMed ID: 30904097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
    Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
    Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuron-Glia Interactions Increase Neuronal Phenotypes in Tuberous Sclerosis Complex Patient iPSC-Derived Models.
    Nadadhur AG; Alsaqati M; Gasparotto L; Cornelissen-Steijger P; van Hugte E; Dooves S; Harwood AJ; Heine VM
    Stem Cell Reports; 2019 Jan; 12(1):42-56. PubMed ID: 30581017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
    Kenerson H; Dundon TA; Yeung RS
    Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
    Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779.
    Messina MP; Rauktys A; Lee L; Dabora SL
    BMC Pharmacol; 2007 Nov; 7():14. PubMed ID: 17986349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
    Boggarapu S; Roberds SL; Nakagawa J; Beresford E
    Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis.
    Kim WS
    Korean J Pediatr; 2011 Jun; 54(6):241-5. PubMed ID: 21949518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetically engineered human cortical spheroid models of tuberous sclerosis.
    Blair JD; Hockemeyer D; Bateup HS
    Nat Med; 2018 Oct; 24(10):1568-1578. PubMed ID: 30127391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin.
    Malhowski AJ; Hira H; Bashiruddin S; Warburton R; Goto J; Robert B; Kwiatkowski DJ; Finlay GA
    Hum Mol Genet; 2011 Apr; 20(7):1290-305. PubMed ID: 21212099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. I-Wire Heart-on-a-Chip II: Biomechanical analysis of contractile, three-dimensional cardiomyocyte tissue constructs.
    Schroer AK; Shotwell MS; Sidorov VY; Wikswo JP; Merryman WD
    Acta Biomater; 2017 Jan; 48():79-87. PubMed ID: 27818306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.